Pathway Financial Advisers LLC Sells 114 Shares of Johnson & Johnson (NYSE:JNJ)

Pathway Financial Advisers LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,049 shares of the company’s stock after selling 114 shares during the period. Pathway Financial Advisers LLC’s holdings in Johnson & Johnson were worth $3,249,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Mirador Capital Partners LP raised its stake in shares of Johnson & Johnson by 4.2% during the first quarter. Mirador Capital Partners LP now owns 20,508 shares of the company’s stock worth $3,244,000 after buying an additional 833 shares during the last quarter. Aviance Capital Partners LLC raised its stake in shares of Johnson & Johnson by 63.3% during the first quarter. Aviance Capital Partners LLC now owns 37,818 shares of the company’s stock worth $5,982,000 after buying an additional 14,663 shares during the last quarter. Skyline Advisors Inc. raised its stake in shares of Johnson & Johnson by 3.5% during the first quarter. Skyline Advisors Inc. now owns 2,478 shares of the company’s stock worth $392,000 after buying an additional 83 shares during the last quarter. Wolff Wiese Magana LLC raised its stake in shares of Johnson & Johnson by 8.0% during the first quarter. Wolff Wiese Magana LLC now owns 3,950 shares of the company’s stock worth $625,000 after buying an additional 294 shares during the last quarter. Finally, BKM Wealth Management LLC raised its stake in shares of Johnson & Johnson by 16.3% during the first quarter. BKM Wealth Management LLC now owns 14,473 shares of the company’s stock worth $2,289,000 after buying an additional 2,025 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Finally, The Goldman Sachs Group reduced their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $160.62 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm’s fifty day moving average price is $163.44 and its two-hundred day moving average price is $155.32. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The firm has a market capitalization of $386.56 billion, a P/E ratio of 10.01, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.46%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the company posted $2.66 earnings per share. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.09%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.